NUVB vs NVS
NUVB: Nuvation Bio is a clinical-stage oncology firm advancing a portfolio of targeted small-molecule therapies for patients with solid tumors, highlighted by its ROS1-positive NSCLC treatment, IBTROZI. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | NUVB | NVS | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $6.93 | $158.86 | |
| Market cap as of 2026-08-24 | $2.4B | $227.4B | |
| P/E as of 2026-08-24 | n/a | 21.95 | |
| PEG as of 2026-08-24 | n/a | 3.66 | |
| Net margin as of 2026-08-24 | -88.2% | +22.5% | NVS higher |
| Gross margin as of 2026-08-24 | +88.2% | +75.0% | NUVB higher |
| Operating margin as of 2026-08-24 | -86.6% | +29.9% | NVS higher |
| ROE as of 2026-08-24 | -49.7% | +29.9% | NVS higher |
| ROA as of 2026-08-24 | -23.5% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-24 | 1.63 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-08-24 | +1083.6% | +3.3% | NUVB higher |
| Dividend yield as of 2026-08-24 | n/a | +3.7% | |
| Beta as of 2026-08-24 | 1.60 | 1.17 | |
| 1-year return as of 2026-08-21 close | +152.9% | +25.3% | NUVB higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.